Arcturus Therapeutics Holdings Inc. — Form 8-K Summary
Business context and reporting period
Arcturus Therapeutics Holdings Inc. filed a current report dated August 1, 2019, covering a registered direct offering of common stock to institutional investors. The filing does not report quarterly or annual operating results.
Financing and key financial metrics
- Shares issued: 945,653 shares of common stock.
- Offering price: $11.50 per share.
- Gross proceeds: $10,875,009.50.
- Estimated net proceeds: Approximately $10.1 million after placement-agent fees and estimated offering expenses.
- Placement-agent compensation: H.C. Wainwright & Co., LLC will receive a cash fee equal to 6.0% of gross proceeds raised from investors, plus $75,000 of expenses.
- Revenue, profit, cash flow, margins, debt and liquidity: The filing does not provide operating results, cash flow data, debt balances, margins or a comprehensive liquidity analysis.
Material changes versus the prior comparable period
The filing does not provide a prior-period comparison. The material event is the planned equity financing, which would increase cash by approximately $10.1 million before consideration of subsequent uses and increase shares outstanding by 945,653 shares upon closing.
Outlook, contingencies and unusual items
- The offering was expected to close on or about August 5, 2019, subject to customary closing conditions; the filing does not confirm the actual closing.
- The shares were registered under the company’s Form S-3 registration statement, declared effective July 29, 2019.
- Proceeds are not allocated to a specific use in the provided filing text.
- The securities purchase agreement contains customary representations, warranties and covenants. The company cautioned that these provisions allocate contractual risk and should not necessarily be viewed as factual statements regarding the company.
- No guidance or detailed management outlook is provided.
Important facts for investors to verify
- Whether the offering closed as planned and the final net proceeds received.
- The resulting increase in shares outstanding and potential dilution to existing shareholders.
- The company’s subsequent use of the approximately $10.1 million in proceeds.
- Updated cash, operating burn rate, debt and liquidity information in later periodic filings.
- Any material developments affecting the representations, warranties, covenants or closing conditions in the securities purchase agreement.